Details for Patent: 10,231,927
✉ Email this page to a colleague
Which drugs does patent 10,231,927 protect, and when does it expire?
Patent 10,231,927 protects XATMEP and is included in one NDA.
This patent has three patent family members in three countries.
Summary for Patent: 10,231,927
| Title: | Methotrexate composition |
| Abstract: | A Methotrexate composition for oral administration is provided comprising a pharmaceutically acceptable salt of Methotrexate and an aqueous carrier agent. The Methotrexate salt is substantially or completely soluble in the aqueous carrier agent, forming an aqueous solution. There is also provided a method of manufacturing a Methotrexate composition for oral administration, comprising mixing a pharmaceutically acceptable salt of Methotrexate with an aqueous carrier agent until the Methotrexate salt is substantially or completely soluble in the carrier agent to form an aqueous solution. |
| Inventor(s): | Tierney; Carl (Leeds, GB), Powell; Stacey (Leeds, GB), Braybrooke; Peter (Leeds, GB), Jones; Geraint (Leeds, GB) |
| Assignee: | Rosemont Pharmaceuticals Ltd. (Leeds, GB) |
| Application Number: | 15/821,242 |
|
Patent Claim Types: see list of patent claims | Use; Composition; Dosage form; |
More… ↓ |
Drugs Protected by US Patent 10,231,927
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Azurity | XATMEP | methotrexate sodium | SOLUTION;ORAL | 208400-001 | Apr 25, 2017 | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | A METHOD FOR TREATING ACUTE LYMPHOBLASTIC LEUKEMIA | ⤷ Subscribe | ||||
| Azurity | XATMEP | methotrexate sodium | SOLUTION;ORAL | 208400-001 | Apr 25, 2017 | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | TREATMENT OF JUVENILE RHEUMATOID ARTHRITIS | ⤷ Subscribe | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 10,231,927
| Foriegn Application Priority Data | ||
| Foreign Country | Foreign Patent Number | Foreign Patent Date |
| United Kingdom | 1200192.1 | Jan 6, 2012 |
International Family Members for US Patent 10,231,927
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| European Patent Office | 2614814 | ⤷ Subscribe | |||
| Spain | 2726524 | ⤷ Subscribe | |||
| United Kingdom | 201200192 | ⤷ Subscribe | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
